DEF 14A: Elicio Therapeutics Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting

Elicio Therapeutics is holding its Annual Meeting of Stockholders on November 7, 2024, to elect directors, ratify the selection of its accounting firm, and approve the issuance of shares related to warrants and a convertible note.

Summary

• Elicio Therapeutics will hold its Annual Meeting of Stockholders virtually on November 7, 2024, at 9:30 a.m. Eastern Time.
• Stockholders will vote on three proposals: electing three directors (Robert Connelly, Yekaterina (Katie) Chudnovsky, and Allen R. Nissenson) to the Board of Directors, ratifying the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approving the issuance of shares of common stock upon the exercise of certain warrants and conversion of a convertible note to comply with Nasdaq Listing Rule 5635(b).
• The Board of Directors recommends voting 'For' all proposals.
• The record date for determining stockholders eligible to vote is September 11, 2024.
• The company is seeking approval for the potential issuance of shares related to warrants and a convertible note issued to GKCC, LLC, controlled by director Yekaterina (Katie) Chudnovsky.
• If all warrants are exercised and the convertible note is converted, GKCC, LLC could hold approximately 51.98% of Elicio's common stock, triggering Nasdaq Listing Rule 5635(b) requiring stockholder approval.
• The company engaged Alliance Advisors, LLC as a proxy solicitor for a fee of approximately $12,500 plus expenses.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the upcoming annual meeting and proposals. The potential dilution and change of control are risks, but the company is taking steps to comply with regulations.

Positives

• The virtual format of the Annual Meeting enables greater stockholder attendance and participation, improves meeting efficiency, and reduces costs and environmental impact.
• The Board of Directors is actively engaged in risk oversight through various committees.
• The company has adopted a Clawback Policy to recover excess incentive compensation in the event of an accounting restatement.
• The company has a Code of Business Conduct and Ethics and Corporate Governance Guidelines in place.

Negatives

• The potential issuance of shares could significantly dilute existing stockholders' ownership.
• The concentration of ownership in GKCC, LLC could give them significant influence over company decisions.
• Yekaterina (Katie) Chudnovsky is not considered an independent director due to her significant ownership of the company's securities.

Risks

• Failure to obtain stockholder approval for the share issuance could impact the company's ability to proceed with the warrant exercises and convertible note conversion.
• The potential change of control could have unforeseen consequences for the company.
• The market price of the common stock could decline due to the issuance or resale of common stock to GKCC, LLC.

Future Outlook

The company is obligated to file a registration statement with the SEC by November 15, 2024, for purposes of registering the Conversion Shares for resale by the Purchaser, and to use commercially reasonable efforts to have the registration statement declared effective no later than 30 days after filing such registration statement with the SEC, or in the event the SEC reviews and has written comments to the registration statement, within 90 days following the receipt of such written comments.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors. However, the need to comply with Nasdaq Listing Rule 5635(b) is a common requirement for publicly traded companies when issuing shares that could result in a change of control.

Related Party Transactions

• In December 2023, Elicio entered into a subscription agreement with GKCC, LLC for the issuance and sale of 1,213,000 shares of common stock at $5.81 per share.
• In March 2024, Elicio entered into a subscription agreement with GKCC, LLC for the issuance and sale of pre-funded warrants to purchase up to 1,032,702 shares of common stock at $5.81 per warrant.
• In July 2024, Yekaterina (Katie) Chudnovsky and Jay Venkatesan, each a member of our Board of Directors, along with trusts affiliated with Jay Venkatesan participated in a public offering.
• In August 2024, Elicio entered into a securities purchase agreement with GKCC, LLC to issue a $20.0 million convertible note.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the warrants are exercised and the convertible note is converted.
• The potential change of control could impact the company's strategic direction and operations.
• Employees may be affected by any changes resulting from the potential change of control.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The company needs to obtain stockholder approval to proceed with the warrant exercises and convertible note conversion.
• The company is obligated to file a registration statement with the SEC by November 15, 2024, for purposes of registering the Conversion Shares for resale by the Purchaser, and to use commercially reasonable efforts to have the registration statement declared effective no later than 30 days after filing such registration statement with the SEC, or in the event the SEC reviews and has written comments to the registration statement, within 90 days following the receipt of such written comments.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholder Vote, Board of Directors, Share Issuance, Warrants, Convertible Note, Nasdaq Listing Rule 5635(b), GKCC, LLC, Yekaterina Chudnovsky, Baker Tilly US, LLP, Corporate Governance, Elicio Therapeutics